Aspirin also known as acetylsalicylic acid is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin also has an antiplatelet, or "anti-clotting", effect and is used in long-term, low doses to prevent heart attacks, strokes and blood clot formation in people at high risk for developing blood clots. It has also been established that low doses of aspirin may be given immediately after a heart attack to reduce the risk of another heart attack or of the death of cardiac tissue.
In a new development King Pharmaceuticals Inc. and Acura Pharmaceuticals Inc. have failed to win the approval of a US panel for marketing an experimental painkiller called Acurox.
Low-dose aspirin (LDA) is one of the main agents used for the prevention of thromboembolic vascular events, and has the advantages of both low cost and a prolonged duration of antiplatelet action; however, it is associated with a doubling of the risk of gastrointestinal bleeding, even at doses as low as 75 mg daily. The gender differences in the clinical manifestations of LDA-associated gastroduodenal mucosal injury have not been well studied.
Cumberland Pharmaceuticals Inc. today announced results from a meta-analysis comparing the efficacy and safety of ibuprofen and acetaminophen, which was published in the March edition of the peer-reviewed journal The Annals of Pharmacotherapy. The publication notes that in a majority of evaluated studies ibuprofen demonstrated superior efficacy compared to acetaminophen for the treatment of pain and fever, and found no significant safety differences between the drugs.
Nearly 9 million people in UK suffer from debilitating headaches called migraine and this leads to a severe impairment in quality of life and affects productivity. The headaches associated with an attack may last for several days often bringing nausea and a general feeling of uneasiness in presence of lights and sounds.
A single dose of 900-1000 mg aspirin can substantially reduce migraine headache pain within two hours, for more than half of people who take it. It also reduces any associated nausea, vomiting, and sensitivity to light or sound (photophobia or phonophobia).
New research by the University of East Anglia (UEA) shows no risk in combining two commonly-prescribed treatments for patients at risk of heart attacks and strokes.
Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced that the results of the M118 EMINENCE clinical trial have published in Circulation.
Kaiser Health News: "Consumers and employers who provide health insurance are scrambling to understand what will change in their premiums and benefits once provisions of the recently passed law go into effect." Some of the answers they seek are unclear because the legislation leaves out details the health department must fill in during the regulatory process.
Kaiser Health News staff writer Andrew Villegas writes about how FSA rules are going to be different.
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
Among today's headlines is news about a lawsuit filed by Massachusetts insurers who are seeking to reverse the state insurance commissioner's decision and allow them to raise rates.
Gastroesophageal reflux disease is an important public health problem which is extremely common nowadays. Symptoms of GERD arise from the exposure of increased acid gastric contents into the lower part of the esophageal mucosa. Most patients with GERD have NERD with invisible mucosal damages under endoscopy.
Aspirin, ibuprofen and other non-steroidal anti-inflammatory drugs (NSAIDs) remain the most common treatment to relieve symptoms of arthritis and other inflammatory disorders. But despite their widespread use (around 2.5 million Canadians have osteoarthritis) these medications are also known to cause severe, sometimes life-threatening adverse effects within the body, particularly in the gastrointestinal tract
New research shows that a high level of C-reactive protein, a marker for inflammation in the blood, is associated with brain changes that are linked to problems with executive thinking skills. The study is published in the March 30, 2010, issue of Neurology®, the medical journal of the American Academy of Neurology.
Postmenopausal women who regularly use aspirin and other analgesics (known as painkillers) have lower estrogen levels, which could contribute to a decreased risk of breast or ovarian cancer.
Portola Pharmaceuticals, Inc. today announced that it has initiated its first in human Phase 1 trial in healthy volunteers of PRT062607, a novel, oral Syk-specific kinase inhibitor in development to treat chronic inflammatory diseases, including rheumatoid arthritis (RA), and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. In preclinical in vivo models of RA, PRT062607 was shown to reduce inflammation in a dose-dependent manner.
Physician scientists from the Cedars-Sinai Heart Institute presented new findings on the effectiveness of routine aspirin therapy for preventing heart disease, a drug therapy for atrial fibrillation and the role left ventricular assist devices may play in weight reduction for obese patients with chronic end-stage heart failure who are considered for heart transplantation.
A Westchester patient takes aspirin for pain, but develops rashes and hives. A Bronx patient with a gastrointestinal problem caused by bacteria is prescribed penicillin, then passes out. A Bronx woman is given a contrast dye for an internal diagnostic exam, then her skin peels off.
A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant in the ABCB1 gene. Patients enrolled in the TRITON-TIMI 38 study were treated with dual antiplatelet therapy with either Plavix® (clopidogrel) plus aspirin or Effient® (prasugrel) plus aspirin and managed with percutaneous coronary intervention (PCI) following an acute coronary syndrome (ACS) event.
AstraZeneca (NYSE: AZN) today announced results of a new analysis of the PLATO (A Study of PLATelet Inhibition and Patient Outcomes) study which showed there were fewer deaths in patients with acute coronary syndromes (ACS) who took the investigational oral antiplatelet ticagrelor (BRILINTA™/BRILIQUE™) within seven days prior to having heart bypass surgery (coronary artery bypass graft, CABG) compared to those who took clopidogrel.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.